Senior Vice President, UCB
Dr. Neil Weir is responsible for discovery at UCB, overseeing an integrated portfolio of small molecule and antibody therapeutic projects in the areas of Immunology and Neurology,. The discovery team Neil is responsible for has transitioned twenty novel molecules into development, comprising small molecules and antibodies. Neil was one of the inventors of the drug Cimzia®, a novel pegylated anti-TNF. Prior to his role at UCB. Neil was head of Discovery at Celltech R&D in the UK during which he was involved in the discovery and development of antibody and antibody fragment-based drugs. Dr Weir is a member of the Research Directors Group of EFPIA (The European Federation of Pharmaceutical Industries and Associations) and has sponsored three call topics in the European Innovative Medicines Initiative (IMI). He is a member of the MRC’s Stratified Medicine Steering Group and chair of the ABPI Innovation Board. Dr Weir received a BSc (Hons) in biology from Edinburgh University and a Ph.D. at the Institute of Biotechnology (University of Kent at Canterbury) studying metabolic flux through amino acid biosynthesis pathways.